Janaury 25, 2021 —Canon Medical Systems USA, Inc. has received FDA clearance for the Aquilion Exceed LB CT system, giving clinicians the opportunity to see more during radiation therapy planning for accuracy, precision and speed. As cancer cases continue to increase in the U.S., providing clinicians with the latest technology for accurate simulation across treatment plans remains critical.
The Aquilion Exceed LB supports fast and efficient radiation oncology workflows without compromising on patient position, image quality, or reproducibility. Features include:
- Accuracy even in complex simulations through industry-leading capabilities, like the largest bore opening (90 cm), edge-to-edge extended Field-of-View (90 cm) reconstruction and wide detector coverage (4 cm).
- Better contouring powered by Artificial Intelligence (AI) with sharp, clear and distinct images from Canon Medical’s Advanced intelligent Clear-IQ Engine (AiCE) Deep Learning Reconstruction (DLR) technology.
- Expanded capabilities – the Exceed LB is also uniquely designed to meet the needs of radiology departments requiring the flexibility to handle bariatric patients and challenging patient positioning, and with patient access and technology designed to streamline CT interventions.
“The Aquilion Exceed LB was designed to push the boundaries of traditional simulation,” said Erin Angel, managing director, CT Business Unit, Canon Medical Systems USA, Inc. “Deep learning reconstruction will give radiation oncology teams the confidence they need for accurate and precise planning across patients.”
For more information: us.medical.canon
March 30, 2026 
